|
CDC's ACIP Recommendations include not recommending Afluria for children younger than 9 years, updated influenza vaccine schedule for everyone 6 months and older, guidance for people with egg allergies and discussion of the newly approved quadrivalent vaccine. MMWR 2012;61(32):613.. (8/17/12)
FDA approves 2012-13 Influenza Vaccines. US influenza vaccines for 2012–13 season to contain A/California/7/2009 (H1N1)-like, A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010-like (Yamagata lineage) antigens (8-13-12 FDA News Release)
Narcolepsy and
Pandemirix.
WHO safety
committee
indicates
possible
association
between a novel
adjuvanted H1N1
influenza
vaccine used in
Europe and onset
of narcolepsy in
children. The
Pandemirix
vaccine was not
used in the
United States
and at present
we are unaware
of any
associations
between any
other vaccines
and the onset of
narcolepsy in
adolescents
which is a rare
genetic
disorder.
- GACVS/WHO -
Statement on
Narcolepsy and
vaccination
(04-21-11)
- Montastruc JL,
Durrieu G,
Rascol O.
Pandemrix,
(H1N1)v
influenza and
reported cases
of narcolepsy.
Vaccine
2010;29(11).
Older Information
All 2009
H1N1 vaccine
monovalent
vaccine
manufactured in
2009 and
distributed in
the United
States
expired by
September 15,
2010,
regardless of
the date on the
label.
link to CDC
The
Advisory
Committee on
Immunization
Practices (ACIP)
Recommends
Influenza
Vaccine to
everyone older
than 6 months of
age.
The ACIP
recommendation,
likely to be
accepted by the
CDC Director and
HHS Secretary,
will apply to
the 2010/11 flu
season.
CDC Press
Release
2-24-2010
Certain lots of
Sanofi Pasteur's
H1N1 in
pre-filled
syringes should
be used by
February 15,
2010.
There
are no safety
concerns with
these lots, the
shelf life is
just shorter
than indicated
on the lable.
[02-02-10]
More
information,
including lot
numbers |
CDC Q&A
Nasal
Spray H1N1
Vaccine Recalled
Due to Decreased
Potency.
The 13 lots of
MedImmune's
vaccine are
being recalled
due to sub-par
potency; not
because of
safety concerns.
Most doses are
believed to have
been
administered
while they were
fully potent.
[12-12-09]
More info,
including lot
numbers |
CDC Q&A
Non-Safety-Related
Recall of
Certain Lots of
Sanofi Pasteur
H1N1 Pediatric
(0.25mL, for
6-35 month olds)
Vaccine in
Pre-Filled
Syringes.
Sanofi
Pasteur has
recalled this
vaccine because
of decreased
potency - not
because of
safety concerns
- in these lot
numbers:
UT023DA,
UT028DA,
UT028CB,
UT030CA.
[12-15-09]
More info
CDC summary of adverse events following
2009 influenza
vaccines
reported to
VAERS.
Enhanced
surveillance for
vaccine safety
is being
conducted this
year. No unusual
adverse events
have been
identified as
causally related
to the 2009 H1N1
vaccines.
MMWR 12-04-09
The US
FDA approved
Novatis'
seasonal
influenza
vaccine,
Agriflu.
This
single dose
vaccine is for
ages 18 and
older.
FDA Press
Release 11-27-09
Flu
Vaccine
Monitoring
information
provided by
Uppsala
Monitoring
Centre (in
Sweden).
Lists countries
using H1N1
vaccine,
publishing AEFI
reports, etc.
UMC Page
The US
FDA approved
CSL's influenza
vaccines for
infants and
children.
Both
the seasonal and
the H1N1 by CSL
are now approved
for children as
young as 6
months.
FDA
Press Release
11-12-09
The US
FDA approved
GlaxoSmithKline's
H1N1 vaccine.
With
this latest
approval, there
are now 5 H1N1
vaccines
approved
in the US.
FDA
Press Release
11-16-09
GlaxoSmithKline's
seasonal
influenza
vaccine,
Fluarix, has
been approved by
the US FDA to
include ages
3-17 years.
The prior
approved use was
adults 18 years
and older.
Fluarix is does
not protect
against H1N1; it
is the vaccine
for the 2009/20
seasonal flu.
FDA Press
Release 10-19-09
Monitoring
influenza
vaccine safety.
With
support from the
CDC, we have
created an
automated
internet-based
system that will
follow-up on any
self-reported
adverse symptoms
to influenza
vaccine after
vaccination.
more information
about the survey
|
Washington Post
article on this
effort
The US
FDA approved
four H1N1
vaccines. Three
are traditional
shots;
MedImmune’s is a
nasal spray
similar to
FluMist (the
other
manufacturers
are CSL,
Novartis and
sanofi Pasteur).
These vaccines
are expected to
be available to
the public in
October, some
lots may be
available
earlier. The
people
recommended to
receive the
vaccine first
are children 6
months to 4
years, pregnant
women,
caregivers to
infants younger
than 6 months,
health
care/emergency
workers who
directly deal
with patients
and kids 5-18
years with
chronic medical
conditions. more
info at
WebMD.
"Prepare
for a Vaccine
Controversy"
- on H1N1
flu/vaccine and
how the
government
should explain
the risks.
Op-Ed by Arthur
Allen in
August 1 2009
NYTimes
With the new
H1N1 virus
continuing to
cause illness,
hospitalizations
and deaths in
the US during
the normally
flu-free summer
months and some
uncertainty and
about what the
upcoming flu
season might
bring, CDC's
Advisory
Committee on
Immunization
Practices has
taken an
important step
in preparations
for a voluntary
novel H1N1
vaccination
effort to
counter a
possibly severe
upcoming flu
season. On July
29, 2009, ACIP
met to consider
who should
receive novel
H1N1 vaccine
when it becomes
available.
more info from
CDC
ACIP
Recommendations
on the
Prevention and
Control of
Seasonal
Influenza with
Vaccines.
MMWR July 31,
2009.
pdf
|html
The US
FDA
approved
FluMist,
by MedImmune,
for use in
people 2-49
years of age.
This expansion
now includes
children 2-5
years of age.
FDA Press
Release
(9-19-07)
The US FDA
approved Glaxo
SmithKline's
FluLaval
influenza virus
vaccine.
FluLaval is for
adults 18 years
and older to
protect against
strains of
influenza
projected to
impact the
Northern
Hemisphere in
the 2006/07 flu
season. FluLaval
is manufactured
by ID Biomedical
Corp (a Canadian
subsidiary of
GlaxoSmithKline)
and distributed
by GSK.
FDA Press
Release
(10-05-06)
The US FDA
announces
approval of
Fluarix,
an inactivated
influenza
vaccine for
adults. Fluarix
is manufactured
in Germany by a
subsidiary of
GlaxoSmithKline. FDA
Press Release
(08-31-05)
CDC's
guidelines for
controlling
influenza
transmission in
long-term care
facilities
(11-15-07).
PDF (150k)
|
HTML version
A new
Influenza
vaccine will be
available for
the 2005/6 Flu
Season: The
FDA has approved
the license
supplement of
sanofi pasteur)
to market a
formula of their
influenza
vaccine produced
without
introducing
preservatives at
any step in the
manufacturing
process. Fluzone®,
Influenza Virus
Vaccine, No
Preservative,
Pediatric Dose
is the only
influenza
vaccine approved
for use in the
U.S. in children
as young as 6
months. The
vaccine will be
available in
0.25 mL
pediatric dose
and 0.50 mL for
children 3 years
and older.
(03-09-05)
The Centers for
Disease Control
and Prevention
has a web page
devoted to the
Seasonal Flu
containing a
wide variety of
information and
updates
including the a
US map showing
flu influenza
activity.
The FDA and CDC
address rumors
about influenza
vaccines
(10-17-03). Information
from a Press
Release.
|